Fifty-five canine parvovirus type 2 (CPV) samples, 12 fecal specimens and 43 cell culture isolates, were examined for their genetic characteristics of VP2 gene. They were collected from the diseased dogs at various districts of Japan during 27 years from 1980 to 2006. A fragment of VP2 gene was analyzed by restriction fragment length polymorphism assay and DNA sequencing. The original antigenic type 2 of CPV (CPV-2) was no longer found in the samples since 1984, and two antigenic variants CPV-2a and CPV-2b replaced CPV-2 as predominant types for about 5 years from 1982. A new genetic variant of prototype CPV-2a with non-synonymous substitution at the VP2 amino acid residue 297 from Ser to Ala was first detected in 1987. New CPV-2b with the same amino acid substitution at position 297 as new CPV-2a was also detected from the samples collected in 1997. Since then new CPV-2b has been the predominant CPV over the field of Japan. Several additional amino acid substitutions were detected in the VP2 gene of some recent CPV strains. Neither CPV-2c(a), CPV-2c(b), nor "Glu-426" of the antigenic variants previously found outside the country was detected in any samples tested. Reactivity of new CPV-2a and 2b variants against antibodies produced by the current vaccine products was determined by a cross hemagglutination-inhibition test. The recent field CPV isolates reacted more efficiently to the antibodies produced in dogs vaccinated with the new CPV-2b vaccine strain than the conventional CPV-2 vaccine strain.
Canine parvovirus type 2 (CPV) suddenly emerged around 1978 [1] and is now well recognized as a clinically most important enteric pathogen for puppies. CPV originated most probably from feline panleukopenia virus (FPLV) or FPLV-like parvovirus species of wild carnivores and spread worldwide showing rapid adaptation to dogs [33, 42, 45] . Soon after the original antigenic type 2 of CPV (CPV-2) emerged, two antigenic variants, CPV-2a and CPV-2b (CPV-2a/2b), were discovered in field CPV isolates and they were distinguished each other based on subtle antigenic differences recognized by the monoclonal antibodies [14, 34, 36] . These antigenic variants replaced CPV-2 throughout the world and became as predominant antigenic types of CPV since the beginning of 1980's. After that, another amino acid substitution was detected in prototype CPV-2a/2b viruses in Europe [3, 47] : amino acid residue at position 297 of VP2 changed from Ser to Ala, although this substitution involved no antigenic change. They are called "new CPV-2a" and "new CPV-2b" [25] , and have been circulating as predominant CPV among domestic dogs in the world showing various ratios of these 2 types in each country [4, 7, 9-12, 16, 20, 26, 31, 37, 47, 48] .
Recently, novel antigenic CPV variants have been described. They are CPV-2c(a) and CPV-2c(b) viruses which were isolated from Vietnamese leopard cats in 1997 [18, 19] , and "Glu-426" virus which was detected from Italian dogs in 2000 [5] . CPV-2c(a) and 2c(b) have a naturally occurring mutation in the VP2 residue 300 Gly to Asp from the new CPV-2a and 2b VP2, respectively, and they could be serologically distinguished from the previous antigenic types [18, 31] . CPV-2c(a) was also identified in a dog in Korea [20] , suggesting the circulation of CPV-2c(a) type in domestic dog population. The "Glu-426" of which amino acid residue at position 426 of new CPV-2b VP2 changed from Asp to Glu was first detected as a genetic variant of new CPV-2b in Italy [5] . Similar virus was isolated also from a Vietnamese dog in 2002 and the monoclonal antibody study of Nakamura et al. [32] testified that this Vietnamese isolate was an antigenic variant of CPV. It was subsequently confirmed by using the monoclonal antibody 21C3 generated by Nakamura et al. [32] that Italian "Glu-426" isolates also showed similar antigenic profile to the Vietnamese isolate [25] . On the other hand "Glu-426" has been called as "CPV-2c" in Europe recently [8] , resulting in unwanted confusion [21] and concern [ 26, 46] in relation to the formerly described CPV-2c(a)/2c(b) antigenic variants.
For more efficient prophylaxis, monitoring the current state of CPV evolution in the field is necessary. Therefore the genetic variations in the total of 55 CPV samples collected from domestic dogs between 1980 and 2006 were examined. In addition, reactivity of recent field CPV isolates against antibodies produced by the current vaccine products were analyzed.
MATERIALS AND METHODS

Clinical specimens and viruses:
A total of 55 CPV samples that consist of 12 fecal specimens and 43 cell culture isolates were examined. They were collected from dogs showing typical clinical signs of parvovirus disease at various districts of Japan during 27 years from 1980 to 2006 and stocked in the deep freezer until use.
Polymerase chain reaction (PCR): A fragment of VP2 gene from nucleotide (nt) 3,615 to 4,124 (510 bp) was amplified by using a set of primers. Primers were designed from an alignment of VP2 gene of original CPV-2 strain CPV-b, and nt sequence of the primers are as follows : F4, 5'-CATACATGGCAAACAAATAGAGCATTGGGC-3' (sense orientation; located on the CPV-b whole genome sequence at positions 3,615 to 3,644); R4, 5'-ATTAGTAT-AGTTAATTCCTGTTTTACCTCC-3' (antisense orientation, located at positions 4,096 to 4,124). The test sample was diluted 10 times with sterile distilled water and applied in the PCR. The conditions for the reaction was the same as those described previously [28] .
PCR based restriction fragment length polymorphism (RFLP) (PCR-RFLP): The PCR product was digested with a restriction endonuclease Alu I, and this PCR-RFLP can detect substitution in the VP2 nt at positions 3,675 (from T to G) and 3,684 (from C to T) which are causes of amino acid (aa) change at positions 297 and 300, respectively. The restriction fragments were separated by agarose gel electrophoresis and visualized by staining with ethidium bromide.
As a result, the PCR product of CPV-2 was divided into 4 fragments of 388, 84, 70 and 18 bp. While the PCR product of prototype CPV-2a/2b was divided into 3 fragments of 388, 154 and 18 bp, and the PCR product of new CPV-2a/2b was divided into 4 fragments of 388, 93, 61 and 18 bp.
DNA sequencing: The PCR product of selected 25 samples (6 samples from 1986 to 1990 and 19 samples from 1997 to 2006) as shown in Table 1 were cloned into pCR4-TOPO plasmid vectors (Invitrogen) and sequenced by using the ABI PRISM Big Dye Terminator version 3.0 cycle sequencing kit on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). Sequence analysis was performed by GENETYX-Win version 4.0 (Software Development Co.) to detect "Glu-426" variant as well as to predict either antigenic type of 2a or 2b.
Phylogenetic analysis: Phylogenetic and molecular evolutionary analyses were performed using MEGA version 3.1 [23] . Multiple alignments were carried out using CLUSTAL X version 1.83 [44] , phylogenetic tree was constructed using the neighbor-joining method [40] , and distances were determined using the Kimura two-parameter method [22] .
Nucleotide sequence accession numbers: The nt sequence accession numbers in the NCBI database of the indicated virus used in this study are as follows: original CPV-2 strain CPV-b (M38245); prototype CPV-2a strain CPV-15 (M24003); prototype CPV-2b strain CPV-39 (M74849); new CPV-2a strains OB1 (D26080) and CPV-435 (AY742953); new CPV-2b strains Sho-nan (AB128923) and CPV-436 (AY742955); CPV-2c(a) strains V139 (AB054222), V140 (AB054223) and Pome (EF599098); CPV-2c(b) strain V203 (AB054224); "Glu-426" strains 56/ 00 (AY380577) and HNI-4-1 (AB120727). Serology: Antigenic analysis of the recent field CPV strains was performed by hemagglutination-inhibition (HI) test with polyclonal immune serum. Eight-weeks-old seronegative beagle dogs were immunized two times three weeks apart by canine combined live vaccine products which contain either CPV-2 or new CPV-2b strain. For each strain totally 35 dogs were used and serum sample was collected 3 weeks after the first injection. The HI test was preformed according to the national standard method for CPV serology as originally described previously [41] , and the highest serum dilution showing complete HA-inhibition was regarded as HI titer.
RESULTS
Genetic properties of CPV strains:
The result of PCR-RFLP analysis was shown in Fig. 1 . The restriction enzyme Alu I digestion clearly classified the CPV samples as CPV-2, prototype CPV-2a/2b and new CPV-2a/2b, respectively, although this method could not distinguish 2a and 2b antigenic types. CPV-2 was detected from the samples collected before 1983. Prototype CPV-2a/2b was found in the samples collected between 1980 and 1987. New CPV-2a/2b was first detected in the samples collected in 1987 and exclusively found from the samples after 1990.
Nucleotide sequences of the 25 CPV samples were translated to aa sequence to know aa residues at positions 297 and 426. Deduced aa residues at critical positions were shown in Table 1 . Two samples in 1986 and 1987 were identified as prototype CPV-2b, 5 samples in 1987, 1990 and 1997 were new CPV-2a, and rest of all in 1997, 2000, 2003 and 2006 were new CPV-2b. Some strains, especially isolated in 2006, had one or more novel amino acid substitutions in VP2. However, neither CPV-2c(a)/2c(b) nor "Glu-426" were found in any of the present samples.
Phylogenetic analysis: A phylogenetic tree shown in Fig.  2 was based on the aa sequence from 277 to 446 of the CPV VP2. There were 7 branches formed in the tree and they were CPV-2, prototype CPV-2a, prototype CPV-2b, new CPV-2a, new CPV-2b, CPV-2c(a)/2c(b) and "Glu-426".
Antigenic analysis of the recent field CPV by the cross HI test: Geometric mean HI titers of dog serum samples obtained 3 weeks after the first vaccination against some representative CPV strains were presented in Table 2 . Antibodies produced in the dogs by the vaccine containing CPV-2 strain did not react efficiently with the recent field CPV isolates new 2a/2b when compared with the homologous antigenic type strain. On the other hand, antibodies elicited by the new CPV-2b vaccine strain did react more efficiently with the recent field strains.
DISCUSSION
Three decades have passed since CPV emerged and CPV became a well-known puppy killer virus along with canine distemper virus at clinic site. The incidence of canine parvovirus disease and canine distemper has been decreasing especially in urban area such as Tokyo. Regarding to the FPL that had already been known as parvovirus disease of cats when CPV emerged, the prophylaxis strategy that anti- body-mediated immunity given by the modified live vaccine has been quite successful for the disease control. Naturally enough, the original CPV-2 strain has been adopted as immunogen and still used for vaccine products in many countries. However, unlike FPLV, it turned out soon afterwards that CPV was evolving more rapidly than other DNA viruses [36, 42] . Antigenic variant CPV-2a appeared only several years after emergence of CPV-2. Together with CPV-2b subsequently appeared, antigenic variations among CPV-2, CPV-2a and CPV-2b were pointed out by not only monoclonal [14, 27, 34, 36] but also polyclonal antibodies when carefully analyzed [6, 39] . Under the circumstances it is necessary to keep monitoring CPV circulating in the field, and it has been performed in many countries. A simple and easy genetic analysis has been used frequently and detected many genetically novel CPV variants from canids and felids throughout the world and it appears to show a more geographically defined evolution pattern including Japan [3, 4, 18, 20, 31, 32, 48] . However, not all cases of such genetic mutation cause antigenic changes, or are involved in different biological phenotypes. Only a few of them have rather accidentally come to light and the typical cases are CPV-2c(a) and CPV-2c(b), and "Glu-426". Biological significance of amino acid substitution detected in some recent domestic CPV isolates (Table 1) remains unknown, and further studies may be required to elucidate antigenic changes. The present study revealed two points which were newly clarified for CPV epidemiology in Japan. First, it has clearly demonstrated "replacement from prototype CPV-2a/ 2b to new CPV-2a/2b" in Japanese isolates, although the same fact could be confirmed from the fragmentary data registered in the databases by other studies [15, 17, 18, 29] . However, the key question as to biological significance of the change from prototype CPV-2a/2b to new CPV-2a/2b types remains, because the Ser 297 Ala substitution cannot be distinguished serologically. However, from the point of viral evolution, it is notable that the same Ser 297 Ala change occurred simultaneously to CPV-2a/2b in other countries. It is likely that adaptation of CPV-2a/2b to domestic dogs independently resulted in the same amino acid change all over the world, rather than new CPV-2a/2b emerged in one place and replaced prototype CPV-2a/2b worldwide. This is one feature of the evolution pattern of CPV that we have learnt since its emergence [18, 35, 36] .
The second was no evidence of circulation of either CPV-2c(a)/2c(b) or "Glu-426" variants. These variants were not detected in previous studies performed in the last decade in Japan [11, 12, 15, 30, 32] . The antigenic variants CPV-2c(a)/2c(b), first detected from the Vietnamese wild cats, have the substitution of aa residue at position 300 of VP2 from Gly to Asp [18] . Recently similar CPV-2c(a) virus was detected also from a Korean dog [20] , suggesting the circulation of CPV-2c(a)/2c(b) variants in both canids and felids. The present results suggest that CPV-2c(a)/2c(b) is not actively circulating in Japanese dog populations. Alternatively, CPV-2c(a)/2c(b) exists in Japan but does not cause typical CPV-related symptoms in domestic dogs. If this is the case, we could miss the CPV-2c(a)/2c(b) infection, as our samples were collected from the dogs with typical clinical symptoms.
The "Glu-426" variant was first found from Italy in 2000 and subsequently from Vietnam in 2002. And a recent study discovered similar variant in German archival samples collected in 1996 [10] . These observations suggest that emergence of "Glu-426" occurred independently in different areas. Since "Glu-426" has spread easily between dogs in Italy, "Glu-426" may have some dominant nature against new CPV-2a/2b [24, 25] . Similar viruses are molecularly identified from dogs in European and American countries during the last a couple of years [9, 10, 16, 21, 37] . It is possible that the variant virus has spread from Italy to such areas in some means, although epidemiological relations between Italy and the subsequent areas are uncertain. If this is the case, the pattern of intercontinental transmission looks like how the original CPV-2 spread throughout the world 30 years ago. Further studies will be required to confirm the intercontinental transmission model of the "Glu-426" variant. Intriguingly, this variant has not been detected epidemiologically in Asian and Oceanian countries yet [7, 20, 26, 32, 48] except for a single case of "Glu-426" infection in Vietnam in 2002 [32] . A continuous monitoring, regardless of the past epidemiological mode of CPV emergence and spread in these regions, is essential to understand the CPV evolution and to develop a future strategy for prophylaxis of CPV infection in dogs.
A chronological table of the epidemic strain of CPV in Japan was made based on the present result together with the previous findings [2, 11, 12, 15, 27, 29, 30, 32, 35] . As shown in Table 3 , CPV-2 first appeared at the beginning of 1979 in Tokyo [2] and existed till 1983 in the field. Two antigenic variants CPV-2a and CPV-2b replaced as dominants for about 5 years from 1982 [12] . In 1987, new CPV-2a, a genetic variant of the prototype CPV-2a was first appeared (Table 1) , and it was presumed from the data presented in Fig. 1 together with the previous reports [11, 12] that, for a while afterwards, it remained as a predominant CPV. New CPV-2b, which showed the same amino acid substitution as new CPV-2a, appeared around 1997, and since then, new CPV-2b has been the predominant CPV over the field of Japan [30, 32] .
There have been a few reports describing antigenic disagreement between the original CPV-2 and the subsequent antigenic variants of CPV by using polyclonal antibodies [6, 39]. As a matter of course, the disagreement has raised reasonable concern over the effectiveness of the current vaccine products in which the original CPV-2 is adopted [6, 13, 38, 39, 43] . In the present study, canine antibodies raised after one-shot immunization of the vaccine clearly distinguished between homologous and heterologous antigenic CPV strains (Table 2 ). However, sera obtained 2 weeks after the second injection did not (data not shown). This implies two important insights into the CPV vaccination; one is that there exists some qualitative difference between the initial and secondary immune responses against vaccination, and another is, therefore, that a CPV vaccine strain, which is most closely related to the field antigenic type, is desirable for the maximum vaccination efficacy [46] . Usually puppies are compelled to receive several times injection starting from 6 to 8-weeks-old just because of interference by maternal antibody existed, and meanwhile, they are becoming more susceptible to virulent field CPV in inverse proportion to waning of maternal antibody. Therefore it is critical for puppies to react as early as possible and acquire the immunity conformed to the field antigenic type CPV by less vaccination opportunities.
In conclusion, the present chronological analysis of CPV samples for the last 27 years in Japan suggests that a similar transition to various foreign countries has occurred. New CPV-2b variant virus has been a predominant antigenic type of CPV, while no "Glu-426" has been found. In Japan, most dogs have been vaccinated for CPV infection. Our results suggest that the vaccine immunity did not significantly drive CPV evolution by promoting further mutations in dogs. It is possible that the vaccination has minimized viral replication in the dog populations, which might have led to the minimal spontaneous viral mutations and possible viral evolution in Japanese dogs. It should be noted that we found antigenic CPV variants both CPV-2c(a)/2c(b) and "Glu-426" 10 years ago in carnivores in Vietnam, where the parvovirus vaccination practice had not been performed sufficiently, differing from Japan and Western countries [18, 32] . It is plausible that CPV could have evolved freely in Vietnamese animals with no pre-existing immunity against CPV, which led to different evolutional outcomes.
